Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Recruiting 2Unknown 1Completed 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Gastrointestinal 2Classical hematology 1

Conditions

Marijuana Abuse 2Tourette Syndrome 1Stress Disorders, Post-Traumatic 1Sleep Initiation and Maintenance Disorders 1Severe Acute Respiratory Syndrome 1Seizures 1Parkinson Disease 1Pancreatic Cancer Non-resectable 1Pain 1Opioid-Related Disorders 1Neoplasms 1Multiple Sclerosis 1Marijuana Use 1Inflammatory Bowel Diseases 1Hepatitis C 1Glaucoma 1Fibromyalgia 1Epilepsy 1Depression 1Crohn Disease 1Coronavirus Infections 1Colitis, Ulcerative 1Chronic Traumatic Encephalopathy 1Chronic Pain 1Carcinoma, Hepatocellular 1COVID-19 1Brain Injuries, Traumatic 1Bipolar Disorder 1Autistic Disorder 1Anxiety Disorders 1

Interventions

Cyclophosphamide 3155Cisplatin 3151Carboplatin 2929Paclitaxel 2671Radiotherapy 2643Gemcitabine 2544pembrolizumab 2324Docetaxel 2154Bevacizumab 2126Fluorouracil 1819Capecitabine 1780Oxaliplatin 1709Dexamethasone 1589Nivolumab 1516Doxorubicin 1477Rituximab 1453Etoposide 1341Magnetic Resonance Spectroscopy 1261Irinotecan 1232Leucovorin 1212Cytarabine 1123Pemetrexed 1060Drug Therapy 1060fludarabine 1044Vincristine 956Specimen Handling 928Prednisone 924Cetuximab 919Lenalidomide 916Trastuzumab 897

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Medical Marijuana × Clear all
NCT04827992 2025-11-05

Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain

Massachusetts General Hospital

Phase NA Completed
87 enrolled

Marijuana Use, Marijuana Abuse, Pain

NCT06605430 2025-07-29

CanPan-C

HealthPartners Institute

Phase 2 Recruiting
64 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

NCT06518434 2024-07-24

CanHep

University Medical Center Groningen

Phase 2 Recruiting
20 enrolled
Gastrointestinal

Marijuana Abuse, Carcinoma, Hepatocellular

NCT03944447 2022-06-02

OMNI-Can

OMNI Medical Services, LLC

Phase 2 Unknown
200,000 enrolled
Classical hematology

Chronic Traumatic Encephalopathy, Brain Injuries, Traumatic, COVID-19, Acquired Immunodeficiency Syndrome, Amyotrophic Lateral Sclerosis, Anemia, Sickle Cell, Anxiety Disorders, Autistic Disorder, Bipolar Disorder, Colitis, Ulcerative, Crohn Disease, Depression, Epilepsy, Fibromyalgia, Tourette Syndrome, Glaucoma, Hepatitis C, Sleep Initiation and Maintenance Disorders, Multiple Sclerosis, Opioid-Related Disorders, Neoplasms, Parkinson Disease, Seizures, Stress Disorders, Post-Traumatic, Inflammatory Bowel Diseases, Coronavirus Infections, Severe Acute Respiratory Syndrome, Chronic Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡